Macular Degeneration News and Research

Latest Macular Degeneration News and Research

Study shows complement activation plays an important role in inherited macular degeneration

In a study published on line this week in the journal Human Molecular Genetics, Drs. Donita Garland, Rosario Fernandez-Godino, and Eric Pierce of the Ocular Genomics Institute at the Massachusetts Eye and Ear, Harvard Medical School, along with their colleagues, reported the unexpected finding that in mice genetically engineered to have an inherited form of macular degeneration, turning off the animals' complement system, a part of the immune system, prevented the disease.

20 Aug 2013

Omega-3 rich oils improve membrane fluidity in retina cells and help fight age-related eye diseases

Scientists working at the Research Center on Aging at the Health and Social Services Centre - University Institute of Geriatrics of Sherbrooke (CSSS-IUGS) have been studying strategies for protecting retinal pigment epithelium (RPE) cells.

16 Aug 2013

Oraya Therapy Stereotactic Radiotherapy for treatment of wet AMDs now available at Optegra

Oraya Therapeutics, Inc. announced today that the Oraya Therapy Stereotactic Radiotherapy for the treatment of wet age-related macular degeneration (AMD) is now available at Optegra Manchester Eye Hospital, becoming the second facility in the UK to provide the therapy.

14 Aug 2013

Regeneron, Bayer report positive results from Phase 3 VIVID-DME and VISTA-DME trials of EYLEA for DME

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that in the Phase 3 VIVID-DME and VISTA-DME trials of EYLEA (aflibercept) Injection for the treatment of diabetic macular edema, EYLEA 2 milligrams (mg) dosed monthly and EYLEA 2 mg dosed every two months (after 5 initial monthly injections) achieved the primary endpoint of a significantly greater improvement in best-corrected visual acuity from baseline compared to laser photocoagulation at 52 weeks.

6 Aug 2013

New NIH projects to target Fragile X syndrome, nicotine addiction and AMD

The National Institutes of Health has launched three innovative projects that will focus on development of therapeutics for Fragile X syndrome, nicotine addiction, and age-related macular degeneration. These projects are funded through the NIH Blueprint Neurotherapeutics Network which provides access to a variety of drug development resources.

1 Aug 2013

Excessive exposure to ultraviolet light can damage the eyes, says ophthalmologist

When it comes to damaging sun rays, skin protection is a top priority for many. But there is another area that needs to be brought into focus - the eyes.

23 Jul 2013

University of Florida receives RPB Sanders Construction grant

Research to Prevent Blindness has awarded a prestigious, one-time laboratory grant of $600,000 to the Department of Ophthalmology at the University of Florida, College of Medicine. The newly created laboratory will be permanently named the RPB Mildred Krahmer Sanders and William Clifford Sanders Laboratory for Vision Research.

20 Jul 2013

IVAN study: Lucentis and Avastin effective in treating wet AMD

An anti-cancer drug has been proven to be equally as effective in treating the most common cause of blindness in older adults as a more expensive drug specifically formulated for this purpose.

20 Jul 2013

Researchers discover new protein that encourages ‘bad’ blood vessel growth

The discovery of a protein that encourages blood vessel growth, and especially 'bad' blood vessels - the kind that characterise diseases as diverse as cancer, age-related macular degeneration and rheumatoid arthritis - has been reported in the journal Nature.

18 Jul 2013

Aflibercept drug shows minor added benefit for overall survival in colorectal cancer patients

The drug aflibercept (trade name: Zaltrap) has been approved in Germany since February 2013 in combination with a certain chemotherapy for adults with metastatic colorectal cancer in whom chemotherapy with oxaliplatin could not stop the disease from progressing.

12 Jul 2013

UC Riverside professor receives grant to study potential treatment for age-related macular degeneration

A University of California, Riverside bioengineering professor has received a two-year, $120,000 grant to search for chemical compounds that have the potential to treat age-related macular degeneration.

12 Jul 2013

Tel Aviv researcher says lessons from Israel's health-care system could optimize eye health

According to the World Health Organization, 80% of blindness is preventable or treatable - but it remains a severe health concern across the globe, even in industrialized countries.

11 Jul 2013

Ohr Pharmaceutical enrolls first 60 patients in OHR-002 Phase II clinical trial for wet-AMD treatment

Ohr Pharmaceutical, Inc., a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced that it has enrolled the first 60 patients in the Company's ongoing OHR-002 Phase II clinical trial evaluating Squalamine Eye Drops for the treatment of the wet form of age-related macular degeneration.

10 Jul 2013

Research suggests new models for study of Barrett's esophagus

Research focused on the regulation of the adult stem cells that line the gastrointestinal tract of Drosophila suggests new models for the study of Barrett's esophagus.

28 Jun 2013

Ico Therapeutics completes Phase 2 iDEAL study for treatment of diabetic macular edema

iCo Therapeutics Inc. announced today that it has completed enrollment of its Phase 2 iDEAL study evaluating the efficacy and safety after repeated injections of iCo-007 in patients with Diabetic Macular Edema (DME). The study has shown a good safety profile with no drug-related serious adverse events to date.

19 Jun 2013

Eylea can ease vision problems for wet AMD patients

There is no cure for age-related macular degeneration, an eye disease that is the leading cause of vision loss and blindness in older Americans. Last year, the National Institutes of Health reported that two drugs injected into the eyes, Avastin and Lucentis, eased symptoms for sufferers, especially those in the advanced, "wet" stage of the disease, when blood vessels in the eye become swollen and leak fluids in the eye.

19 Jun 2013

Omeros gets regulatory clearance to begin Phase 1 clinical trial of OMS721

Omeros Corporation today announced that it has obtained regulatory clearance to start the Phase 1 clinical trial evaluating OMS721, the Company's lead human monoclonal antibody from its mannan-binding lectin-associated serine protease-2 (MASP-2) program.

13 Jun 2013

Effective method to restore sight to patients with blinding diseases

Researchers at the University of California, Berkeley, have developed an easier and more effective method for inserting genes into eye cells that could greatly expand gene therapy to help restore sight to patients with blinding diseases ranging from inherited defects like retinitis pigmentosa to degenerative illnesses of old age, such as macular degeneration

13 Jun 2013

Rapamycin improves cardiac function in mice suffering from age-related heart disease

Elderly mice suffering from age-related heart disease saw a significant improvement in cardiac function after being treated with the FDA-approved drug rapamycin for just three months.

11 Jun 2013

Aflibercept drug used for AMD shows no added benefit over current standard therapy

The drug aflibercept (trade name: Eylea) has been approved in Germany since November 2012 for the treatment of wet age-related macular degeneration (AMD). In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG) the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether this new drug offers an added benefit over the current standard therapy.

7 Jun 2013

Macular Degeneration News and Research

Latest Macular Degeneration News and Research

Study shows complement activation plays an important role in inherited macular degeneration

Omega-3 rich oils improve membrane fluidity in retina cells and help fight age-related eye diseases

Oraya Therapy Stereotactic Radiotherapy for treatment of wet AMDs now available at Optegra

Regeneron, Bayer report positive results from Phase 3 VIVID-DME and VISTA-DME trials of EYLEA for DME

New NIH projects to target Fragile X syndrome, nicotine addiction and AMD

Excessive exposure to ultraviolet light can damage the eyes, says ophthalmologist

University of Florida receives RPB Sanders Construction grant

IVAN study: Lucentis and Avastin effective in treating wet AMD

Researchers discover new protein that encourages ‘bad’ blood vessel growth

Aflibercept drug shows minor added benefit for overall survival in colorectal cancer patients

UC Riverside professor receives grant to study potential treatment for age-related macular degeneration

Tel Aviv researcher says lessons from Israel's health-care system could optimize eye health

Ohr Pharmaceutical enrolls first 60 patients in OHR-002 Phase II clinical trial for wet-AMD treatment

Research suggests new models for study of Barrett's esophagus

Ico Therapeutics completes Phase 2 iDEAL study for treatment of diabetic macular edema

Eylea can ease vision problems for wet AMD patients

Omeros gets regulatory clearance to begin Phase 1 clinical trial of OMS721

Effective method to restore sight to patients with blinding diseases

Rapamycin improves cardiac function in mice suffering from age-related heart disease

Aflibercept drug used for AMD shows no added benefit over current standard therapy

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Empowering genomics research with cloud-based innovation

Macular Degeneration News and Research

Latest Macular Degeneration News and Research

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Empowering genomics research with cloud-based innovation

Newsletters you may be interested in